secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immix Biopharma, Inc. (IMMX)
CIK:        0001873835
Form:       8-K
Filed at:   2021-12-20T23:59:59+00:00
Accession:  0001493152-21-032048
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immix Biopharma closes IPO of 4.2M shares at $5.00/share for $21M gross proceeds
--------------------------------------------------------------------------------

- IPO closed Dec 20, 2021; shares began trading on Nasdaq Dec 16 under IMMX.
- Gross proceeds $21M; underwriters have 45-day option for up to 630K additional shares.
- Net proceeds to fund IMX-110 Phase 2a trial in soft tissue sarcoma and combination trial.
- Also fund IND-enabling studies for IMX-111 (colorectal cancer) and IMX-120 (inflammatory bowel disease).
- Filed amended charter and bylaws in connection with IPO closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873835/000149315221032048/0001493152-21-032048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873835/000149315221032048/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-032048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer